KRAS and lung cancer: G12C, which is well-known for its high detection rate in lung cancer and the recent development of its inhibitor sotorasib [23], was observed only in 2.2% of KRAS mutant PDAC patients, and none in ACC, ASC, and ACP patients (Fig. 3c).